Eli Lilly (LLY)

These stocks have been raising their payouts for years and they're likely going to continue doing so for the foreseeable future.

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.

Krispy Kreme's stock rose 3.81% after hours on Wednesday, following FBI Director Kash Patel's testimony about his stock purchase, despite a 68.28% drop in 2025.

The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.

FBI Director Kash Patel was asked about two stocks he bought earlier this year by a member of Congress on Wednesday and gave a surprising answer. The transactions come as members of Congress are working on legislation to ban lawmakers and cabinet members from buying and selling stocks.

Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug and device capabilities.

Eli Lilly's orforglipron showed significant weight loss, improved blood sugar, and reduced inflammation in adults with obesity or overweight in a Phase 3 trial.

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

A news article implied that the company might have an advantage in the weight loss drug race.

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable strength of its diabetes and obesity care segments. The company's flagship weight-loss drug, Wegovy, and the diabetes treatment Ozempic continued their meteoric

The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.

Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments.

In an otherwise hot stock market, healthcare stocks are underperforming.

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

Quality yields above 6% from three very different market sectors.

The weight loss drug market may reach $95 billion within five years.